BiotechTube
Home/Huadong Medicine (HD Medicine)/Zhang Hailong
ZH

Zhang Hailong

Chief Scientific Officer (CSO) / Head of R&D

Huadong Medicine (HD Medicine)

Therapeutic Areas

OncologyAutoimmune DiseasesMetabolic Diseases

Huadong Medicine (HD Medicine) Pipeline

DrugIndicationPhase
HDM1002 (Sovleplenib)Primary Immune Thrombocytopenia (ITP)NDA Submitted
HDM2002 (Mitazalimab)Metastatic Pancreatic CancerPhase III
HDM3001 (PRV-3279)Systemic Lupus Erythematosus (SLE)Phase II
TTP273Type 2 DiabetesPhase II
HDM5001Advanced Solid TumorsPhase I

Leadership Team at Huadong Medicine (HD Medicine)

LL
Lv Liang
Chairman of the Board
LB
Li Boting
General Manager (CEO)
View full Huadong Medicine (HD Medicine) profile